Organisation paid for research Program year 2025 Source: CMS Open Payments

Bukhalo Michael MD

Neither a doctor nor a teaching hospital

Research payments

$2,148,796

54 payments

Through program year 2025, Bukhalo Michael MD is reported as receiving $2,148,796 in research payments, across 54 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$35,117	2
2024	Research	$34,043	2
2023	Research	$58,570	3
2022	Research	$127,842	6
2021	Research	$423,267	7
2020	Research	$368,892	11
2019	Research	$1,101,064	23

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $2,148,796 54 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $757,608 6 payments
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $286,150 3 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $241,986 4 payments
A Multicenter Study With A Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed By A Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-1 $222,453 2 payments
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $188,224 3 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $148,616 6 payments
Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-To-Severe Plaque Psoriasis $91,378 5 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3375880 in Adult Subjects With Moderate-To-Severe Atopic Dermatitis: the Admire Study $80,254 3 payments
A 12 Week Multicenter Randomized Double Blind Placebo-Controlled Study Comparing the Efficacy and Safety of Ly2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With A Long Term Extension Period $42,213 1 payment
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $35,051 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.